Affymax, Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Release: OMONTYS® (Peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United States
4/24/2012 9:07:57 AM
PALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (NASDAQ:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that OMONTYS® (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the United States. OMONTYS is co-marketed by Affymax and Takeda Pharmaceuticals U.S.A. (TPUSA) and distributed by TPUSA. See below for Full Indication, Limitations of Use and Important Safety Information including Boxed WARNINGS.